Allogene back on track after clinical trial hold withdrawn

11 January 2022
lab_biotech_research_pipettes_big

Off-the-shelf cancer med company Allogene Therapeutics (Nasdaq: ALLO) has been cleared to resume clinical trial work after the US regulator determined its technology was not at fault for an observed chromosomal abnormality in a patient.

Announced in October 2021, the trial hold hollowed out the firm’s stock price, as investors worried that its technology could be fatally flawed.

Despite the apparently positive outcome, shares in the company ticked downwards following the announcement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology